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The development of procedures to treat arterial
occlusive disease represents an important achieve-
ment in surgery. Besides vascular surgery, novel
interventional techniques have reached a high level
of accomplishment. However, restenosis remains the
major obstacle to satisfactory long-term patency
after therapeutic interventions for the treatment of
vascular disease.1 All forms of reconstruction,
whether interventional or surgical, cause a degree of
injury to the vessel wall, which results in a wound
healing response. Intimal hyperplasia (IH) is defined
as the early postinterventional migration of smooth
muscle cells (SMCs) and myofibroblasts into the
subintimal space of the vessel, and it leads to cell
proliferation and the production of excessive
amounts of matrix proteins.2 Recent studies have
shown that, in addition to IH through its produc-
tion of a physical mass, changes can occur in arterial
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wall geometry. Defined as arterial remodeling, these
changes also play an important role by altering the
artery circumference because of fibrotic contraction
or compensatory dilatation. This process of arterial
remodeling and the degree of IH together deter-
mine whether, and to what extent, restenosis will
develop in an artery.3 Although the molecular basis
of vascular postinterventional renarrowing is not
fully understood, the development of restenotic
lesions has been shown to involve the production of
specific matrix molecules such as procollagen type I
and the large chondroitin proteoglycan versican.4,5
These molecules modulate cell function (migration,
proliferation), the activity of growth factors, and
local concentrations of lipids in the vascular wall.6
Cell-matrix interactions may also provide the basis
for constrictive remodeling, which resembles a simi-
lar phenomenon in a nonvascular injury response.7
Among numerous mechanical and pharmacolog-
ic approaches, several current investigations, such as
gene therapy8 and ionizing irradiation,9 have been
investigated to inhibit the occurrence of restenosis.
However, only intravascular stents and ionizing irra-
diation have been proved to clinically reduce this
process.10,11
Photodynamic therapy (PDT) is an effective,
alternate experimental approach to favorably modu-
late this vascular healing response,12,13 and a first
clinical trial for primary atherosclerotic plaque
reduction has demonstrated the feasibility of vascu-
lar PDT in humans.14 PDT represents an application
of phototherapy in which visible, wavelength-specif-
ic light is applied to activate otherwise inert photo-
sensitizer dyes to produce free-radical moieties,
without the generation of heat.15 With the absorp-
tion of light, the produced reactive molecular species
exert their effects by damaging cellular organelles
and membranes15 and by affecting extracellular
matrix molecules.16 The acute effects of PDT on
blood vessels result in the eradication of the cells in
the vascular wall without causing thrombosis or
inflammation, and no structural deterioration of the
blood vessel wall has been noted in long-term exper-
iments.12,17 Because restenosis is essentially a focal
obstruction, the precise and strictly local cytotoxic
effects of PDT seem to be very well suited for
endovascular therapy.13 However, the clinical use of
this promising approach to inhibit restenosis was, in
part, limited by the lack of a suitable, readily avail-
able, inexpensive, and, therefore, clinically appropri-
ate photosensitizer.
Methylene blue (MB) is a drug used clinically for
staining purposes18 and for the treatment of
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methemoglobinemia.19 It is a photosensitizer, which
has also been investigated for topical treatment in
PDT.20 The MB has a maximum light absorption at
more than 650 nm, which allows deep and homoge-
nous tissue penetration by light that is unaffected by
blood. MB does not cause skin photosensitization to
ambient light, as other early photosensitizers do.
This study was designed to get further insights
into the molecular aspects of PDT-induced changes
in the vascular wound healing response and to devel-
op a suitable approach for inhibiting restenosis with
a clinically appropriate photosensitizer. This was
achieved by performing morphometric analyses of
the arteries and quantifying messenger RNA
(mRNA) expression of repopulating adventitial cells
for procollagen type I and versican after PDT with
local delivery of MB.
MATERIALS AND METHODS
Experimental design. Male Sprague-Dawley
rats (Charles River Breeding Laboratories,
Wilmington, Mass), weighing 350 to 420 g, were
anesthetized with intraperitoneal ketamine (50
mg/kg), xylazine (5 mg/kg), and atropine (40
µg/kg). Common carotid artery balloon injury (BI)
was performed by using a 2F Fogarty embolectomy
catheter (Baxter Health Care, Edwards Division,
Irvine, Calif).21 In brief, the balloon was introduced
into the common carotid artery and inflated with
0.65 mL of air. After three passages, the embolecto-
my catheter was removed, and a 22-gauge polyeth-
ylene catheter was advanced through the external
carotid artery into the common carotid artery,
which was isolated with microclamps. The catheter
was connected with a three-way stopcock to a
Statham transducer for synchronous pressure moni-
toring (HP 78205C, Hewlett Packard, Mass). The
MB (American Regent Laboratories, Shirley, NY)
was diluted in 5% dextrose and lactated Ringer’s
solution (Abbott Laboratories, Chicago, Ill), and
pilot studies (data not included) indicated a final
concentration of 250 µg/mL to be optimal for
PDT. Under low ambient light, the drug was inject-
ed into the common carotid artery with 180 mm Hg
for 2 minutes. After local delivery, MB was aspirated
from the arterial lumen, the artery was flushed with
saline, and the catheter was removed. The external
carotid artery was ligated, and the blood flow was
restored.
The animals were randomly assigned to these
three groups: 
1. group PDT (n = 6), BI followed by application
of photosensitizer and laser irradiation;
2. group PS (n = 6), BI followed by the photosen-
sitizer MB application alone;
3. group BI (n = 6), no treatment other than BI to
the carotid artery.
Because laser light irradiation alone does not
change the vascular injury response in this model,21
this group was not included.
Animals had free access to a standard rat chow
(Purina rat chow 5001, Ralston Purina, St Louis,
Mo) and water while they were maintained in a stan-
dard 12-hour light/dark cycle. An independent insti-
tutional animal care committee approved all proce-
dures. Animal care complied with the “Principles of
Laboratory Animal Care” and the “Guide for the
Care and Use of Laboratory Animals” (Institute of
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council. Washington:
National Academy Press, 1996).
Methylene blue localization studies. Three
animals were used to determine the MB photosensi-
tizer distribution in the arterial wall. The animals
were killed 5 minutes after BI and local MB delivery
to the left carotid artery, in the manner described.
The arterial system was flushed with saline, and the
carotid arteries were excised, embedded in tissue tek
O.C.T. compound (Miles Elkhart, Ind), and stored
at –70°C. Cross sections, 5 µm thick, were covered
with phosphate buffered saline, and the distribution
of MB in the artery wall was determined by using a
confocal microscope (TCS NT, Leica, Wetzlar,
Germany). Digital images were captured with an exci-
tation of 476 nm and an emission between 620 and
630 nm. The contralateral, nonphotosensitizer impreg-
nated carotid artery served as a negative control.
Photodynamic therapy. Five minutes after local
delivery of MB, the common carotid artery was
externally irradiated with 660 nm laser light, emitted
by a diode laser (Alto-Surgeon SRG-3, Polaroid,
Cambridge, Mass), to deliver a total fluence of 100
J/cm2 at an irradiance of 100 mW/cm2. The diode
laser was coupled to a 600-µm optical fiber through
a microlens to obtain a uniform 1-cm spot. The tar-
geted artery was submerged in 0.9% saline and
placed on a right-angled reflective mirror to achieve
uniform irradiation, in a manner previously
described.12 The irradiated vessel segment was
marked with periadventitial india ink.
Harvest. Animals were killed 14 days after
surgery with an overdose of pentobarbital. The iliac
artery was then cannulated, and the arterial system
was flushed with saline and in situ perfusion-fixed at
150 mm Hg with 10% buffered formalin. The bal-
loon-injured vessel segments and the contralateral
carotid artery were excised and placed in fresh 10%
buffered formalin. After embedding in paraffin, mul-
tiple 4-µm thick cross sections were obtained from
the proximal, middle, and distal vessel segments.
Vessel histomorphometry. The histologic
analyses of the arteries stained with hematoxylin and
eosin comprised both a descriptive and quantitative
morphometric evaluation. The morphometry of the
arteries was measured with a digitizing measurement
system (Color CCD Camera Model 2222-1040,
COHU, San Diego, Calif) and analyzed with the
Scion Image software (Scion, Frederick, Md).
Intimal area, medial area, and vessel diameter, as
delineated by the external elastic lamina, were mea-
sured and calculated in a manner described earli-
er.21,22 The external elastic lamina was used as the
reference for the vessel diameter, because compen-
satory or constrictive arterial remodeling processes
include changes at the level of the external elastic
lamina. In addition, adventitial cells were counted
manually and were expressed as the number of cells
per high-power microscopic field (400×). Because
the area of the adventitia varied within the different
specimens, random high-power fields were used for
all quantitative measurements of adventitial cell
numbers and gene expression in the in situ
hybridization experiments.
Digoxigenin in situ hybridization. Groups for
in situ hybridization included PDT, BI, and the
uninjured contralateral artery (n = 3). Because no
differences between the BI and PS groups were
revealed by means of histologic and morphomet-
ric analyses, which suggested no MB-induced
modulation of the vascular wound healing
response, the PS group was not included in the in
situ hybridization experiments. Complementary
DNAs (cDNAs) for type I procollagen and versi-
can core protein were obtained as polymerase
chain reaction fragments, with each gene-specific
primer, in which reverse primers contain a T7
RNA polymerase recognition sequence, at their 5’
end. Primer sequences were for procollagen type
I, TGACTTCAGCTTCCTGCCTCAGCC and
TAATACGACTCACTATAGGGAGGCCCTG
GAGGAGCAGGGCCTTCTTG23; for versican,
GGAGACGACTGTCTTGGTGGCCCAG and
T A A T A C G A C T C A C T A T A G G G A G -
G A C A G C C A G C C G T A A T C G C A . 2 4
Digoxigenin-labeled antisense RNA probes were
synthesized by using an RNA labeling kit
(Boehringer, Mannheim, Germany) according to
the manufacturers’ instruction, and the in situ
hybridization protocol was used with modifica-
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tions, in a manner described earlier.25 Arterial sec-
tions were deparaffinized in xylene and rehydrated
through graded ethanol solutions, washed, and
treated with 5 µg/mL proteinase K (Boehringer) for
30 minutes at 37°C. The specimens were acetylated
in 0.25% acetic anhydride in 0.1 mol/L tri-
ethanolamine for 10 minutes at room temperature,
partially dehydrated through graded ethanol solu-
tions, and briefly dried. Digoxigenin-labeled RNA
probes (1 µg/mL) were added in hybridization
buffer (50% deionized formamide, 10 mmol/L Tris-
HCl [pH 7.6], 0.6 mol/L NaCl, 10% dextran sul-
phate, 1X Denhardt’s solution, 0.25% sodium dode-
cyl sulfate, 10 mmol/L EDTA, 0.2 mg/mL yeast
total RNA), and slides were incubated at 60°C
under coverslips overnight. The coverslips were then
carefully removed, and the sections were rinsed with
50% formamide solution. The hybridized probes
were detected by using an alkaline phosphatase con-
jugated antidigoxigenin monoclonal antibody
(Boehringer), and the colored product was visual-
ized with nitro blue tetrazolium (Boehringer) and 5-
bromo-4-chlor-indonyl-phosphate (Boehringer) as
substrates. For color development, the sections were
incubated for 30 minutes with a procollagen I probe
and for 1 hour with a versican probe at room tem-
perature. Slides were mounted with glycerin jelly
and were kept at 4°C. Five random high-power
microscopic fields (400×) of the adventitia per spec-
imen were digitized (Color CCD Camera Model
2222-1040, COHU, San Diego, Calif), and an
image pixel analysis of the five data points per speci-
men was performed in a blinded fashion, by using a
modification of a method described earlier (IP-lab
spectrum, Scanalytics, Fairfax, Va), to quantify and
statistically evaluate differences in adventitial gene
expression.26 In brief, a segmentation of stained
(positive for gene expression) versus unstained (neg-
ative for gene expression) areas per microscopic field
was performed by setting a specific threshold value
for all slides. The area of positive pixels is presented
as a percentage of the area of all pixels per high-
power field. For statistical analysis, the median data
point of every specimen was assessed and used to
compare control versus PDT procollagen type I and
versican gene expression.
Statistical evaluation. All values are expressed
as the mean plus or minus SD. Differences between
pairs of means were analyzed by means of a one-way
analysis of variance (ANOVA) with Tukey’s honest-
ly significant difference test. Differences in adventi-
tial cell numbers and mRNA expression were deter-
mined by means of the 2-tailed unpaired Student t
test. Five data points per specimen were obtained for
analyzing the mRNA expression. The median values
for each specimen (N = 3/group) were compared
(Statistica, Statsoft, Tulsa, Okla). Differences were
considered significant at a P value less than .05.
RESULTS
At the time of harvest, all animals appeared
healthy and had no evidence of weight loss or
wound infection. Animals treated with MB showed
no signs of toxicity. No artery thrombosis was
observed.
Methylene blue localization
Fig 1 summarizes the findings of the distribution
of MB in the carotid artery after local delivery. There
Fig 1. Fluorescent micrographs of rat common carotid
arteries directly after balloon-injury, untreated (A) or after
the local delivery of 250 µg/mL methylene blue (B). The
internal elastic lamina (arrow) is noted. Excitation of
unstained frozen sections was performed at 476 nm with
a fluorescence capture between 620 and 630 nm. Note the
high-fluorescence signal throughout the vessel wall after
local delivery of the photosensitizer. The scale bar equals
50 µm.
B
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was a faint background signal of the extracellular
matrix in control arteries (Fig 1, A). However, 5
minutes after local delivery of the dye, a strong
homogenous fluorescent signal was detected in the
entire thickness of the arterial wall (Fig 1, B).
Light microscopy and vessel histomorphometry 
The PDT-treated arteries had a denuded luminal
surface, with occasional platelets, but without evidence
of microthrombi, inflammation, or intimal thickening.
The media was devoid of cells and consisted of a nor-
mal matrix tissue and a normal-appearing elastic lami-
na. In contrast, IH formation was demonstrated in the
arteries from the BI and PS groups. In these two
groups, the media showed typical histomorphologic
architecture with several laminae, interspersed with
cells. The adventitia of all groups comprised loose con-
nective tissue interspersed with fibroblast-like cells (Fig
2, A and B). No significant difference in the number
of adventitial cells per high-power field was noted
(PDT, 39 ± 9.4; BI, 45 ± 6.3), and these cells occu-
pied topographically similar positions.
The areas of IH in the BI and PS groups were
revealed by means of morphometric analyses to be
not significantly different (BI, 0.192 ± 0.006 mm2;
PS, 0.183 ± 0.005 mm2), in contrast with the PDT
group, which had no neointimal formation (0 ± 0
mm2; P < .0001; Table I). The media was markedly
thickened after BI and PS (BI, 0.082 ± 0.003 mm2;
PS, 0.085 ± 0.005 mm2), compared with PDT and
uninjured control arteries (PDT, 0.063 ± 0.004
mm2; Control, 0.056 ± 0.003 mm2; P < .05; Table
I). In all groups, no changes in vessel diameter were
found at 2 weeks.
In situ hybridization
Versican. Uninjured control arteries did not
express the proteoglycan versican in any layer of the
arterial wall. Two weeks after BI alone, adventitial
cells and cells in the innermost layers of the neointi-
ma expressed significant amounts of versican
mRNA. The repopulating adventitial cells after PDT
also expressed versican, but the quantity was signifi-
cantly less (BI, 2.93% ± 0.61%; PDT, 1.13% ±
0.39%; P < .02; Fig 3, A and B).
Procollagen type I. Uninjured control arteries
did not express procollagen type I in any layer of the
arterial wall. Two weeks after BI alone, adventitial
cells and cells in the innermost layers of the neointi-
ma expressed significant amounts of procollagen
type I mRNA. The repopulating cells in the adven-
titia of PDT-treated arteries expressed less procolla-
gen type I mRNA; however, this difference did not
reach statistical significance (BI, 4.67% ± 1.02%;
PDT, 4.13% ± 1.25%; P < .09; Fig 4, A and B).
Fig 2. Light micrographs of rat common carotid arteries
stained with hematoxylin and eosin 2 weeks after balloon-
injury, untreated (A) or photodynamic therapy-treated (B).
The internal elastic lamina (arrow) is noted. In photody-
namic therapy-treated arteries, no intimal hyperplasia was
seen; the media was cell free. The scale bar equals 50 µm.
Table I. Morphometric analyses of intimal hyper-
plasia areas, media areas, and artery diameters
2 weeks
Area of IH (mm2 ± SD)
PDT 0 ± 0*
BI 0.192 ± 0.006
PS 0.183 ± 0.005
Area of media (mm2 ± SD)
PDT 0.063 ± 0.004†
Uninjured control 0.056 ± 0.003
BI 0.082 ± 0.003
PS 0.085 ± 0.005
Diameter (mm ± SD)
PDT 0.95 ± 0.04
Uninjured control 0.91 ± 0.05
BI 0.94 ± 0.05
PS 0.93 ± 0.06
*P < .001 (PDT vs BI and PS).
†P < .05 (PDT and uninjured control vs BI and PS).
IH, Intimal hyperplasia; PDT, photodynamic therapy; BI, balloon
injury; PS, balloon injury and photosensitizer only.
B
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DISCUSSION
The occurrence of restenosis after all forms of
reconstruction, whether interventional or surgical, is
an unsolved problem. This study demonstrated that
local delivery of the clinically available photosensi-
tizer dye MB can be effectively used for vascular
PDT to inhibit IH and favorably modulate the
postinterventional vascular wound healing response
at the molecular level in vivo.
The development of IH after BI of the rat
carotid artery has been well studied. The simplicity
of the rat model has facilitated analyses of the cellu-
lar response to injury and the identification of mol-
ecules that play a role in the pathogenesis of resteno-
sis. Numerous vascular PDT studies have also used
this model, and a significant experience was acquired
for PDT dosimetry, histology, and healing respons-
es.12,27,28 In addition, the basic principle of local
delivery in the rat model by means of direct intralu-
minal pressure to deliver the photosensitizer to a
vessel segment has been investigated with the lipo-
somal dye benzoporphyrin-derivative.29 The ability
of vascular PDT to inhibit IH in the rodent model
was also confirmed in large animal models.30,31
However, because of dosimetry issues, these were
short-term experiments, and the development of IH
was not completely inhibited.
The development of IH is known to be maximal
at 2 weeks in this model,12 the point selected to
study the arteries after PDT treatment. In addition,
at this point, it was possible to evaluate the PDT-
induced changes on the repopulating adventitial
cells known to be involved in remodeling.32
The development of postinterventional resteno-
sis is a complex phenomenon, and numerous initiat-
ing and perpetuating factors have been implicated.
Recently, specific matrix molecules, such as procolla-
gen type I and versican, have been implicated in
modulating cell function and, therefore, modulating
the development of restenosis.4,5,33 The upregula-
Fig 3. Localization and quantitation of versican messen-
ger RNA in the rat common carotid arteries stained 2
weeks after balloon-injury, untreated (A) or photodynam-
ic therapy-treated (B). The internal elastic lamina (arrow)
is noted. The scale bar equals 50 µm.
Fig 4. Localization and quantitation of procollagen type I
messenger RNA in the rat common carotid arteries stained
2 weeks after balloon-injury, untreated (A) or photody-
namic therapy-treated (B). The internal elastic lamina
(arrow) is noted. The scale bar equals 50 µm.
A
B
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tion of procollagen type I mRNA and subsequent
production of collagen type I is a distinct phenome-
non after arterial injury6 and has been associated
with fibrosis and constrictive remodeling.33
Versican, a major chondroitin sulfate proteoglycan,
is required for proliferation and migration of mes-
enchymal cells. Therefore, it plays a key role in the
vascular wound healing response and also in athero-
genesis.5 Versican mRNA production is also upregu-
lated in nonhuman primate atherosclerotic arteries
at 2 weeks after experimental angioplasty33 and has
been shown to promote the development of
restenosis in humans.34 The gene expression of both
molecules was investigated in this study to investi-
gate the molecular aspects of the PDT-induced
modulation of vascular wound healing. Versican and
procollagen type I are suggested to be regulated on
a pretranslational level, because the amount of
mRNA expression and the amount of the synthe-
sized protein were found to be proportional.33,35
However, it has been shown that the accumulation
of mature collagen type I depends not only on pro-
collagen type I mRNA expression, but also on its
posttranslational processing and collagen degrada-
tion.36 In this study, PDT of balloon-injured arter-
ies resulted in a down-regulation of versican, which
might be an important factor for the successful long-
term inhibition of restenosis by PDT after vascular
injury. The presence of functional growth factors in
the vascular wall is of major importance for the accu-
mulation of proteoglycans such as versican.37,38 By
its production of free radicals, PDT inactivates
growth factors located in the vessel wall,16,39 which
thereby may result in lower gene expression of versi-
can by the adventitial cells.
In contrast to versican, the gene expression of
procollagen type I in the adventitia was not signifi-
cantly decreased by PDT. Collagen type I mRNA
levels have been shown to be downregulated by
growth factors such as basic fibroblast growth fac-
tor.40 This growth factor has been shown to be func-
tionally inactivated in the matrix after PDT,16 and
this may explain, in part, why there was no signifi-
cant difference between PDT and balloon-injured
control arteries in the quantity of procollagen type I
gene expression. In addition, although there is no
statistical difference in gene expression, posttransla-
tional mechanisms may lead to the different
amounts of the protein in the PDT and control
groups.41
The morphologic appearance of the vessel 2
weeks after PDT with local delivery of MB is identi-
cal to that of PDT with different photosensitizers
and different application modalities.17,21 This is not
unexpected, because all photosensitizers exert their
unspecific effects by the generation of free-radical
moieties. These PDT-treated vessels demonstrated a
lack of IH and an acellular media. In experiments
with the clinically unavailable photosensitizer chlo-
raluminum sulfonated phthalocyanine, inhibition of
IH without arterial degeneration was shown for as
long as 6 months after PDT,42 and it is highly likely
that the long-term response to PDT with MB would
be as favorable.
For vascular PDT, photosensitizers have been
successfully administered systemically in different
animal models.13,30 Despite the selectivity of con-
fined light irradiation, the site-specific delivery of a
photosensitizer directly into a site of vascular inter-
vention has conceptual appeal.43 First, it would
achieve specific local drug concentrations. Second,
concentrating the drug at the target site, and thus
avoiding substantial systemic dosing, could mini-
mize systemic adverse effects. Third, with the use of
specific local, luminal delivery parameters, the pho-
tosensitizer can be confined to predetermined layers
of the artery wall.29
An important aspect of site-specific drug delivery
and PDT is the concern about combined BI, pres-
sure-delivery, and PDT, all discrete injuries to the
vascular wall. However, it has been shown that even
infusion with pressures higher than the 180 mm Hg
used in this study did not accelerate the postinter-
ventional development of IH in the rat carotid
artery model.29 The vessel wall thickness in this
model is much smaller than that of a human vessel
and did not support the use of specialized delivery
catheters, developed for human-size vessels.
However, double-balloon catheters, which create a
protected space at the site of delivery that allows for
prolonged balloon inflation and prolonged drug
delivery, have been successfully shown to deliver
drugs to arteries in a pig model without creating
measurable injury.44 As with the double balloon-
catheter, a sealed compartment was created in the rat
carotid artery by using vessel clamps to introduce
MB at an elevated pressure. Novel microporous
catheter systems, which offer improved functional
characteristics compared with porous balloons, are
being developed in an effort to improve effective
local delivery of drugs to human-size vessels and to
minimize additional injury to the arterial wall.45
As in many experimental studies, limitations of
this investigation are related to the animal model
and the delivery mode. The rat carotid artery bal-
loon injury model produces considerable IH and
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mRNA expression of fibroproliferative factors,
which have been shown to play an important role in
the human vascular injury response.34 However, this
animal model is a well-recognized model of IH, but
not restenosis, and the response in this model may
not represent the prototype of a restenotic lesion in
humans. Because of the different artery size and the
presence of arteriosclerotic plaque, the local applica-
tion of drugs to human arteries may require modi-
fied devices. Nevertheless, vascular PDT by means of
a local drug delivery concept with a clinically avail-
able photosensitizer inhibits the development of IH
and decreases adventitial cell versican gene expres-
sion. It can be performed safely and appears promis-
ing as a strategy to prevent restenosis in humans.
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DISCUSSION
Dr Donaldson (Boston, Mass). I want to thank you for
an excellent presentation, Dr Heckenkamp, and for the
opportunity to reread an extraordinary series of articles
and work that your laboratory has produced in a field that
I think you and your colleagues can take credit for open-
ing. This is a very interesting approach to neointimal
hyperplasia. The paradox is that you can apply light with a
photosensitizer that results in a nondiscriminate release of
free radicals to the entire vessel wall, but create relatively
specific ablation of the neointimal response to injury and
even more miraculously end up with an endothelial cell
cover over the intimal surface. The fact that you have seen
this consistently over the years is tantalizing. You should
be credited for pausing to work on the mechanisms, rather
than plunging ahead with clinical applications.
I have several questions about your findings. You have
chosen a 2-week study interval because in the injured
model, that appears to be the peak of intimal hyperplasia
expression. Can you reassure us that over time there is not
a progressive reaction that leads to either late restenosis or
other kinds of deterioration of the vessel wall?
In your study, you used a fairly high pressure of 180
mm to inflate the vessel to deliver the methylene blue. It
would seem that this added pressure element of injury may
be excessive. There was uptake of versican mRNA in the
adventitia, supporting this possibility. Is 180 mm really
necessary? Can you get away with painting methylene blue
on an open artery, for example, rather than pressure infla-
tion for delivery?
You used a normal, small caliber rat model and took
pains to use reflectors to be sure that light was distributed
throughout the vessel. How does this translate to the thick
disease calcified clinical model?
This technique is sure to be appealing for endovascu-
lar application. How do you envision endovascular deliv-
ery to the site of a coronary or “ peripheral “ angioplasty,
for example?
Dr Heckenkamp (Boston, Mass). Thank you, Dr
Donaldson, very much for your comments.
To start with the first question, why did we choose 2
weeks, and do we expect any progression or how can we
be sure that disease will not progress? In previously pub-
lished studies from our laboratory but also from others
who work with PDT, it has been shown that the very
favorable effect in inhibiting intimal hyperplasia is not only
limited to a short period of time but can be assessed also
up to 6 months after PDT treatment. Since the initial
response to PDT with methylene blue is very similar to the
response we saw with other photosensitizers in this model,
we assume that the long-term outcome will be as favorable
as we saw with other photosensitizers.
The second question, why did we choose a pressure
delivery with 180 mm Hg? In this small animal model,
more appropriate catheters for delivery, for drug delivery
into humans, could not be used because of the small size
of the artery. It has been shown that even higher pressures
in this model do not lead to additional injuries to the arte-
rial wall. We definitely have to choose another catheter
equipment to apply this drug into arteriosclerotic and
larger human tissues. This technology has improved a lot
during these years, and we are confident that we could
apply methylene blue with a different modality to larger
calcified vessels as well. That answers more or less why we
use a rat model for that. There is a lot of data available for
PDT in the rat model. There is a lot known about the
wound healing response in the rat model and about the
dosimetry in the rat model, and we certainly have to mod-
ify these parameters when we want to push this technolo-
gy further into big animal studies and hopefully in the not
too far away future into a clinical trial.
The last question was how can we deliver this method-
ology endoluminal. As I said before, catheter techniques
evolved within the last few years, and we now have the
possibility to deliver laser light into the vessel. With
improvement of local delivery techniques for dyes, we are
also able to deliver dyes into large vessels, and we hope to
overcome the problems seen earlier with big arteries and
photodynamic therapy.
Dr Maciag (Portland, Me). I have two questions. Do
the kinetics of reendothelialization change as a result of
this? If so, or if not, after reendothelialization do you see
again the expression of the procollagen 1 gene?
Dr Heckenkamp. We did not look at the experience of
the procollagen-type 1 gene after reendothelialization. We
know that there is a more rapid reendothelialization after
PDT compared with a deendothelialized vessel without
PDT and that is in part due to inactivation of growth fac-
tors that promote this reendothelialization, but I cannot
tell you if after reendothelialization we have the same
amount of mRNA expression for collagen-type 1.
Dr Maciag. Did you look at catylase or superoxide dis-
mutase gene expression?
Dr Heckenkamp. No, we did not.
Dr Rehring (Boston, Mass). Joerg, very nicely done. I
just have a couple of simple questions. First, were both
your control and experimental groups exposed to methyl-
ene blue? That is, did you control for the potential local
effects of methylene blue in the photodynamic group?
Secondly, is there translational data to confirm your
transcriptional data of the upregulation of versican?
Lastly, have you looked at any other markers for inti-
mal hyperplasia or smooth muscle factors that could con-
tribute to your findings?
Dr Heckenkamp. You raise very interesting points. We
included control groups with methylene blue only without
balloon injury. We had control groups with balloon injury
and methylene blue, and the balloon injury plus methyl-
ene blue did change the development of intimal hyperpla-
sia. So the amount of intimal hyperplasia in arteries after
balloon injury compared with arteries with balloon injury
and methylene blue did not change. So the photosensitiz-
er itself had no effect on the development of intimal
hyperplasia. The photochemical effects of the combination
between the dye and the light led to this favorable effect.
We did not look at other markers, and we chose versi-
can and procollagen type 1 for several reasons. Versican is
a very interesting molecule because it has been shown that
it plays a major role in the development of restenosis in
humans and that this molecule is upregulated in arte-
riosclerotic vessels as well. Procollagen type 1 is a molecule
that is associated with constrictive remodeling, and Dr
Geary and his group published a paper in the JVS in 1998
where he looked at the expression of mRNA of procolla-
gen type 1 and the final end product, mature collagen type
1, in baboon vessels. He did not find a difference in the
quantity of mRNA expression and the quantity of the
mature collagen type 1, so we assume that this molecule is
regulated on the pretranslational level. We think that we
can conclude from the mRNA expression to the amount
of the final protein.
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